[Angiotensin-converting enzyme inhibitors. Current indications]

Area of Science:

• Pharmacology
• Cardiovascular Medicine
• Nephrology

Context:

• Angiotensin-converting enzyme (ACE) inhibitors represent a significant class of drugs.
• Their therapeutic applications span multiple chronic conditions, including heart failure, myocardial infarction, and chronic renal insufficiency.
• The underlying pathologies often involve the renin-angiotensin-aldosterone system, where angiotensin II plays a detrimental role.

Purpose:

• To elucidate the mechanisms by which ACE inhibitors mitigate adverse cardiovascular and renal outcomes.
• To highlight the clinical benefits and broad applicability of ACE inhibitors in managing complex diseases.

Summary:

• ACE inhibitors counteract the harmful effects of angiotensin II, such as endothelial dysfunction, altered renal hemodynamics, and cardiac hypertrophy.
• Clinical evidence demonstrates a reduced incidence of fatal and nonfatal myocardial infarction, stroke, end-stage renal disease, and heart failure-related mortality.
• The drug class is characterized by good tolerability and a low incidence of contraindications.

Impact:

• ACE inhibitors have a substantial impact on reducing morbidity and mortality across a spectrum of cardiovascular and renal diseases.
• They represent a cornerstone therapy for conditions like congestive heart failure and atherosclerotic cardiovascular disease.
• Their favorable safety profile supports widespread clinical use and patient adherence.